Stock Analiz

Resmed Inc. (RMD) stock forecast and price target

Price $239.53 · data as of November 13, 2026

12-month price target

Average target$264.33
Upside / downside+10.4%
Analysts17
ConsensusBuy
Low $210.00Average $264.33High $320.00

Gold marker: average target · white marker: today’s price ($239.53)

Analyst ratings

Strong buy 2Buy 7Hold 10Sell 1Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends June 30, 2027
$12.14+8.7%$5.8B
Next fiscal year
ends June 30, 2028
$13.23+8.9%$6.2B
Next quarter
ends December 31, 2026
$2.99+6.4%$1.5B
Quarter after
ends March 31, 2027
$3.06+6.9%$1.5B

Consensus of the analysts covering Resmed, updated daily. In the last 30 days 15 estimates were raised and 4 lowered.

Our model vs. Wall Street

Analysts see 10.4% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Resmed’s intrinsic value about 28% below today’s market value, and it scores 4.2 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Resmed stock price target?

The average 12-month target from 17 analysts is $264.33, 10.4% above the current price of $239.53 Targets range from $210.00 to $320.00.

Is Resmed a buy according to analysts?

The consensus rating is “Buy” (2 strong buy, 7 buy, 10 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.

How much is Resmed expected to earn?

Analysts expect EPS of $12.14 for the fiscal year ending June 30, 2027 and $13.23 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.